{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:47:52Z","timestamp":1791820072861,"version":"4.3.4"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To perform a systematic review with meta-analysis for evaluating the prevalence of aggressive beta-lactams pharmacokinetic\/pharmacodynamic (PK\/PD) target attainment, identifying predictors of aggressive PK\/PD target nonattainment, and assessing the impact of attaining aggressive beta-lactams PK\/PD targets on clinical efficacy in critical pediatric patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      PubMed-MEDLINE and Scopus databases were independently searched from inception to March 02, 2026. Randomized controlled trials or observational studies evaluating the prevalence of aggressive beta-lactams PK\/PD target attainment (defined as 100%\n                      <jats:italic toggle=\"yes\">f<\/jats:italic>\n                      T\n                      <jats:sub>&gt;4xMIC<\/jats:sub>\n                      ) in critical pediatric patients were included. Independent predictive factors for aggressive beta-lactams PK\/PD target nonattainment and the relationship with clinical outcome were further investigated for qualitative or quantitative analysis. Meta-analysis was performed by pooling odds ratios (ORs) extrapolated from studies providing adjustment for confounders using a random-effects model with an inverse variance method.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 1472 articles were screened, and 8 observational studies were included (724 critical pediatric patients who received 761 beta-lactams treatment courses). The proportion of critical pediatric patients who attained aggressive beta-lactams PK\/PD targets was 5.6%\u201376.2%. An estimated glomerular filtration rate \u226590\u2009mL\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      [OR: 3.01; 95% confidence interval: 1.15\u20137.90;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 52.5%] and male gender (OR: 1.88; 95% CI: 1.10\u20133.22;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 17.25%) emerged as significant independent predictors of failure in attaining aggressive PK\/PD targets. Meta-analysis for the PICO 2 question was unfeasible due to a lack of adjusted data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Our findings showed that a remarkable proportion of critically ill pediatric patients failed in attaining aggressive beta-lactams PK\/PD targets, especially when receiving intermittent\/extended infusion delivery, identifying an estimated glomerular filtration rate \u226590\u2009mL\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      and male gender as potential independent risk factors.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005429","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:03:00Z","timestamp":1791817380000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Aggressive PK\/PD Target Attainment With Beta-lactams in critically Ill Pediatric Patients Having Suspected or Documented Gram-negative Infections\u2014Prevalence, Risk Factors of Nonattainment and Impact on Clinical Outcome"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-3779","authenticated-orcid":false,"given":"Milo","family":"Gatti","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna"},{"name":"Clinical Pharmacology Unit, Department of Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Giorgi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Department of Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"De Paola","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Department of Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Santarella","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, Department of Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pea","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna"},{"name":"Clinical Pharmacology Unit, Department of Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"R1-20261012","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S2352-4642(24)00140-8","article-title":"The burden and contemporary epidemiology of sepsis in children.","volume":"8","author":"Watson","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"R2-20261012","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: analysis for the global burden of disease study.","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"R3-20261012","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/PCC.0000000000003927","article-title":"Surviving sepsis campaign international guidelines for the management of sepsis and septic shock in children 2026.","volume":"27","author":"Weiss","year":"2026","journal-title":"Pediatr Crit Care Med"},{"key":"R4-20261012","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/QCO.0000000000000681","article-title":"Prolonged infusion of beta-lactam antibiotics for gram-negative infections: rationale and evidence base.","volume":"33","author":"Abdul-Aziz","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"R5-20261012","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13054-024-04911-5","article-title":"Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis.","volume":"28","author":"Gatti","year":"2024","journal-title":"Crit Care"},{"key":"R6-20261012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/idr18010003","article-title":"Raising the bar of PK\/PD target attainment of beta-lactams in daily clinical practice: an effective strategy to overcome resistance development to novel beta-lactams?","volume":"18","author":"Gatti","year":"2025","journal-title":"Infect Dis Rep"},{"key":"R7-20261012","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/14656566.2026.2651279","article-title":"Pharmacological approaches to overcome antimicrobial resistance to novel beta-lactams in MDR gram-negative bacterial infections: current practice and future directions.","volume":"27","author":"Gatti","year":"2026","journal-title":"Expert Opin Pharmacother"},{"key":"R8-20261012","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1093\/cid\/ciac506","article-title":"Beta-lactam antibiotic therapeutic drug monitoring in critically ill patients: a systematic review and meta-analysis.","volume":"75","author":"Pai Mangalore","year":"2022","journal-title":"Clin Infect Dis"},{"key":"R9-20261012","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1001\/jama.2024.9803","article-title":"Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock: a systematic review and meta-analysis.","volume":"332","author":"Abdul-Aziz","year":"2024","journal-title":"JAMA"},{"key":"R10-20261012","doi-asserted-by":"crossref","first-page":"1044683","DOI":"10.3389\/fphar.2022.1044683","article-title":"\u03b2-lactam precision dosing in critically ill children: current state and knowledge gaps.","volume":"13","author":"Tang Girdwood","year":"2022","journal-title":"Front Pharmacol"},{"key":"R11-20261012","doi-asserted-by":"crossref","first-page":"114220","DOI":"10.1016\/j.jpeds.2024.114220","article-title":"Prolonged beta-lactam infusions in children: a systematic review and meta-analysis.","volume":"275","author":"Briand","year":"2024","journal-title":"J Pediatr"},{"key":"R12-20261012","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1097\/PCC.0000000000002951","article-title":"Suboptimal beta-lactam therapy in critically ill children: risk factors and outcome.","volume":"23","author":"Van Der Heggen","year":"2022","journal-title":"Pediatr Crit Care Med"},{"key":"R13-20261012","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/CCM.0000000000002817","article-title":"\u03b2-lactam therapeutic drug management in the PICU.","volume":"46","author":"Cies","year":"2018","journal-title":"Crit Care Med"},{"key":"R14-20261012","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00467-019-04205-x","article-title":"Augmented renal clearance: a common condition in critically ill children.","volume":"34","author":"Van Der Heggen","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"R15-20261012","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s40272-020-00426-y","article-title":"Optimizing the use of antibiotic agents in the pediatric intensive care unit: a narrative review.","volume":"23","author":"Willems","year":"2021","journal-title":"Paediatr Drugs"},{"key":"R16-20261012","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/17425255.2024.2385403","article-title":"Dose optimization of \u03b2-lactam antibiotics in children: from population pharmacokinetics to individualized therapy.","volume":"20","author":"Ngougni Pokem","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R17-20261012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40262-019-00813-w","article-title":"Pharmacokinetics and target attainment of antibiotics in critically ill children: a systematic review of current literature.","volume":"59","author":"Hartman","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R18-20261012","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R19-20261012","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-019-00791-z","article-title":"What antibiotic exposures are required to suppress the emergence of resistance for gram-negative bacteria? A systematic review.","volume":"58","author":"Sumi","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R20-20261012","doi-asserted-by":"crossref","first-page":"e875","DOI":"10.1093\/infdis\/jiaf048","article-title":"Impact of attaining an aggressive PK\/PD target with continuous infusion beta-lactams on the clinical efficacy of targeted therapy of early post-transplant Gram-negative infections in critically ill OLT recipients. An interim analysis of a 3-year prospective, observational, study.","volume":"232","author":"Gatti","year":"2025","journal-title":"J Infect Dis"},{"key":"R21-20261012","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R22-20261012","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R23-20261012","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test.","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R24-20261012","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/INF.0000000000004054","article-title":"Relationship between real-time TDM-guided pharmacodynamic target attainment of continuous infusion beta-lactam monotherapy and microbiologic outcome in the treatment of critically ill children with severe documented gram-negative infections.","volume":"42","author":"Gatti","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R25-20261012","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pedneo.2023.09.008","article-title":"Evaluation of pharmacokinetic pharmacodynamic target attainment of meropenem in pediatric patients.","volume":"65","author":"Alsultan","year":"2024","journal-title":"Pediatr Neonatol"},{"key":"R26-20261012","first-page":"101354","article-title":"Continuous infusion of beta-lactam antibiotics in pediatric intensive care unit: a monocenter before\/after implementation study.","volume":"43","author":"Ragonnet","year":"2024","journal-title":"Anaesth Crit Care Pain Med"},{"key":"R27-20261012","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkaf457","article-title":"\u03b2-Lactam dosing in critically ill children: predictors for target non-attainment.","volume":"81","author":"Schouwenburg","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"R28-20261012","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00431-022-04716-0","article-title":"Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.","volume":"182","author":"Debray","year":"2022","journal-title":"Eur J Pediatr"},{"key":"R29-20261012","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijid.2022.04.052","article-title":"Therapeutic drug monitoring of meropenem and pharmacokinetic-pharmacodynamic target assessment in critically ill pediatric patients from a prospective observational study.","volume":"120","author":"Maimongkol","year":"2022","journal-title":"Int J Infect Dis"},{"key":"R30-20261012","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3390\/jcm14051488","article-title":"A real-life study of prolonged meropenem infusion in neonates and children admitted to intensive care units: are three hours long enough?","volume":"14","author":"Mariani","year":"2025","journal-title":"J Clin Med"},{"key":"R31-20261012","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13054-017-1871-2","article-title":"Identifying \u201cat-risk\u201d patients for sub-optimal beta-lactam exposure in critically ill patients with severe infections.","volume":"21","author":"Abdul-Aziz","year":"2017","journal-title":"Crit Care"},{"key":"R32-20261012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00467-018-4120-2","article-title":"Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?","volume":"35","author":"Dhont","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"R33-20261012","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/phar.2617","article-title":"Scoping review of augmented renal clearance in critically ill pediatric patients.","volume":"41","author":"Rhoney","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R34-20261012","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CCM.0000000000002862","article-title":"Beta-lactam therapeutic drug monitoring in the critically ill children: big solution for infections in small people?.","volume":"46","author":"Roberts","year":"2018","journal-title":"Crit Care Med"},{"key":"R35-20261012","doi-asserted-by":"crossref","first-page":"777854","DOI":"10.3389\/fped.2022.777854","article-title":"Beta-lactams therapeutic monitoring in septic children\u2013what target are we aiming for? A scoping review.","volume":"10","author":"Morales Junior","year":"2022","journal-title":"Front Pediatr"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:03:04Z","timestamp":1791817384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005429"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005429","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]}}}